Cargando…

Ifosfamide, Carboplatin, and Etoposide (ICE) in Combination with Regional Hyperthermia as Salvage Therapy in Patients with Locally Advanced Nonmetastatic and Metastatic Soft-Tissue Sarcoma

Patients with localized relapse of soft-tissue sarcoma (STS) after anthracycline-based chemotherapy have a dismal prognosis, particularly when surgery is not possible. To facilitate resection and improve long-term tumor control, we applied an intensified perioperative treatment consisting of ICE (if...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bücklein, Veit, Limmroth, Christina, Kampmann, Eric, Schuebbe, Gesa, Issels, Rolf, Roeder, Falk, Angele, Martin, Dürr, Hans Roland, Knösel, Thomas, Abdel-Rahman, Sultan, Di Gioia, Dorit, Lindner, Lars H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068144/ https://www.ncbi.nlm.nih.gov/pubmed/32189990 http://dx.doi.org/10.1155/2020/6901678

Ejemplares similares

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma
por: Devi, Kanta, et al.
Publicado: (2023)

Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
por: Sokolova, Alexandra, et al.
Publicado: (2017)

Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy
por: Tay, Tricia, et al.
Publicado: (2022)

Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
por: Arakawa, Yoshiki, et al.
Publicado: (2013)

Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
por: Akce, Mehmet, et al.
Publicado: (2016)

Impact of dexamethasone, etoposide, ifosfamide and carboplatin as concurrent chemoradiotherapy agents for nasal natural killer/T-cell lymphoma
por: HATAYAMA, YOSHIOMI, et al.
Publicado: (2013)

Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
por: NAKAGAKI, Yuki, et al.
Publicado: (2022)

Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study
por: Mi, Mi, et al.
Publicado: (2020)

Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
por: Thatcher, N., et al.
Publicado: (1989)

Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma
por: Tomono, Ayana, et al.
Publicado: (2016)

Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
por: Zhou, Ping, et al.
Publicado: (2015)

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma
por: Mahdy, Ahmed, et al.
Publicado: (2023)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
por: Rezaï, Keyvan, et al.
Publicado: (2007)

Comparison of Nutrition-Related Adverse Events and Clinical Outcomes Between ICE (Ifosfamide, Carboplatin, and Etoposide) and MCEC (Ranimustine, Carboplatin, Etoposide, and Cyclophosphamide) Therapies as Pretreatment for Autologous Peripheral Blood Stem Cell Transplantation in Patients with Malignant Lymphoma
por: Aoyama, Takashi, et al.
Publicado: (2018)

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
por: Park, Hyung-Chul, et al.
Publicado: (2012)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
por: Gentille, Cesar, et al.
Publicado: (2022)

Combination of ifosfamide and etoposide as a salvage regimen for previously treated soft tissue sarcomas: a retrospective single centre study
por: Ribeiro, Luiz Fernando, et al.
Publicado: (2022)

Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
por: Tang, Tiffany, et al.
Publicado: (2020)

Valsalva-Like Retinopathy Secondary to Pancytopenia following Induction of Etoposide and Ifosfamide
por: Prinzi, Robert A., et al.
Publicado: (2015)

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma
por: Requilé, Annelies, et al.
Publicado: (2017)

Carboplatin/etoposide: Neutropenia and thrombocytopenia: case report
Publicado: (2021)

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma
por: Moon, Ji Young, et al.
Publicado: (2017)

VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?
por: Albertsmeier, Markus, et al.
Publicado: (2022)

Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma
por: Albertsmeier, Markus, et al.
Publicado: (2020)

Outcomes of Window Therapy with Carboplatin and Ifosfamide for Pediatric Osteosarcoma: A Case Series
por: Aiba, Hisaki, et al.
Publicado: (2023)

Bendamustine in combination with ifosfamide, etoposide, and vinorelbine (VIBE) is an effective salvage regimen for heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma: a single-center experience
por: Prakash, Gaurav, et al.
Publicado: (2021)

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
por: Xie, Lu, et al.
Publicado: (2021)

Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site
por: Piga, A, et al.
Publicado: (2004)

A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide.
por: McClay, E. F., et al.
Publicado: (1993)

Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: a comparison with a historical control group
por: Safaee, Reza, et al.
Publicado: (2012)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
por: Li, Yue-Ya, et al.
Publicado: (2015)

Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma
por: Michelagnoli, M P, et al.
Publicado: (1999)

Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis.
por: English, M. W., et al.
Publicado: (1996)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022)

A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC).
por: Cerny, T., et al.
Publicado: (1989)

Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
por: Shin, Wonkyo, et al.
Publicado: (2018)

Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis
por: Saito, Shiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_folpbqfh248dolng6u7ee1ein0